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The receptor CTLA-4 has been implicated in control-
ling B cell responses, but the mechanisms by which
CTLA-4 regulates antibody production are not
known. Here we showed deletion of CTLA-4 in adult
mice increased Tfh and Tfr cell numbers and
augmented B cell responses. In the effector phase,
loss of CTLA-4 on Tfh cells resulted in heightened B
cell responses, whereas loss of CTLA-4 on Tfr cells
resulted in defective suppression of antigen-specific
antibody responses. We also found that non-Tfr
Treg cells could suppress B cell responses through
CTLA-4 and that Treg and/or Tfr cells might downre-
gulate B7-2 on B cells outside germinal centers as a
means of suppression. Within the germinal center,
however, Tfr cells potently suppress B cells through
CTLA-4, but with a mechanism independent of
altering B7-1 or B7-2. Thus, we identify multifaceted
regulatory roles for CTLA-4 in Tfh, Tfr, and Treg cells,
which together control humoral immunity.
INTRODUCTION
T follicular helper (Tfh) cells are a specialized subset of CD4+
T cells that stimulate germinal center (GC) B cells to produce
high-affinity antibodies. The critical role for Tfh cells in B cell re-
sponses is highlighted by the lack of class-switched antibodies
in mice lacking Tfh cells (Crotty, 2011). Tfh cells are identified
by expression of CXCR5, the chemokine receptor that directs
them to GCs (Breitfeld et al., 2000; Crotty, 2011). Tfh cells also
express high amounts of the transcription factor Bcl6, which is
thought to control the Tfh cell program (Johnston et al., 2009;
Yu et al., 2009; Nurieva et al., 2009). Tfh cells are controlled by
positive costimulatory signals through the inducible T cell costi-
mulator (ICOS) and CD28 receptors, as well as coinhibitory sig-
nals through programmed death 1 (PD-1). ICOS promotes Tfh
cell generation and maintenance, whereas PD-1 inhibits Tfh dif-
ferentiation and/or exit into the blood (Akiba et al., 2005; Choi
et al., 2011; Good-Jacobson et al., 2010; Hams et al., 2011; Ka-
wamoto et al., 2012; Sage et al., 2013).1026 Immunity 41, 1026–1039, December 18, 2014 ª2014 Elsevier InT follicular regulatory (Tfr) cells are a newly defined, special-
ized effector subset of T regulatory (Treg) cells that suppress B
cell responses (Chung et al., 2011; Linterman et al., 2011; Wol-
lenberg et al., 2011). Like Tfh cells, Tfr cells express high levels
of CXCR5, which directs them to GCs. The ability of Tfr cells to
suppress B cell responses might be unique to Tfr cells because
CXCR5 Treg cells are unable to strongly suppress some GC B
cell responses (Chung et al., 2011; Sage et al., 2013; Wollenberg
et al., 2011). However, the precise role of Tfr versus non-Tfr Treg
cells in controlling B cell responses remains undetermined. Tfr
cells are controlled by positive and negative costimulatory sig-
nals, and ICOS and CD28 promote Tfr cell development (Linter-
man et al., 2011; Sage et al., 2013), whereas PD-1 attenuates
both Tfr cell generation and suppressive function (Sage et al.,
2013). It has been proposed that within the GC, the relative pro-
portions of Tfr to Tfh cells (as well as their functional capacity)
control B cell responses and not absolute numbers of either
cell type (Sage et al., 2013).
Although CTLA-4 has been implicated in controlling B cell re-
sponses, the mechanism by which CTLA-4 regulates antibody
production remains unknown. CTLA-4 is a key mediator of
Treg cell function and also controls conventional T cells.
CTLA-4 is constitutively expressed in Treg cell subsets, but
induced upon activation in T conventional cells (Walker, 2013).
Germline deletion of CTLA-4 results in fatal multiorgan inflamma-
tion within 2 to 4 weeks of age (Tivol et al., 1995; Waterhouse
et al., 1995), as well as increased antibody levels (Bour-Jordan
et al., 2003; Walker et al., 2003). Treg-specific deletion of
CTLA-4 recapitulates this great increase in antibody production,
pointing to an essential role for CTLA-4 on Treg cells in limiting B
cell responses (Wing et al., 2008). However, it is not yet clear
whether CTLA-4 suppresses B cell responses by controlling
Tfr, Treg, and/or Tfh cells, due to the lethality associated with
CTLA-4 global and Treg cell-specific deficiency, and the inability
for blocking antibodies to target specific cells.
There are data supporting cell-intrinsic and cell-extrinsic
mechanisms by which CTLA-4 exerts its effects (Corse and Alli-
son, 2012; Walker and Sansom, 2011; Walunas et al., 1996;
Wang et al., 2012). CTLA-4 binds to B7-1 (CD80) and B7-2
(CD86) with higher affinity than CD28. In vitro studies have
demonstrated that CTLA-4 can attenuate B7-1 or B7-2 expres-
sion on dendritic cells either by downregulation or transendocy-
tosis (Onishi et al., 2008; Qureshi et al., 2011; Wing et al., 2008).
Whether CTLA-4 attenuates B7-1or B7-2 expression in vivo orc.
Immunity
CTLA-4 on Tfh, Tfr, and Treg cellswhether these CTLA-4 mediated cell-extrinsic mechanisms con-
trol B cell responses are still unclear.
Here we investigate cellular mechanisms by which CTLA-4
regulates B cell responses using CTLA-4 inducible knockout
strategies. We analyzed how CTLA-4 controls Tfh, Tfr, Treg,
and B cell responses. Our studies showed that CTLA-4 inhibited
Tfh and Tfr cell differentiation and/or expansion.We also demon-
strated that CTLA-4 mediated the suppressive capacity of differ-
entiated Tfr cells. We did not find evidence that Tfr cells downre-
gulate B cell B7-1 or B7-2 throughCTLA-4 in GCs; however, Treg
and/or Tfr cells might downregulate B7-2 on B cells outside the
germinal center via CTLA-4. Our studies reveal multifaceted
roles for CTLA-4 on Tfh, Tfr, and Treg cells in regulating humoral
immunity.
RESULTS
T Follicular Regulatory Cells Express Large Amounts
of CTLA-4
To begin to understand the function of CTLA-4 in controlling B
cells, we assessed CTLA-4 expression in Tfh and Tfr cells. We
immunized mice with NP-OVA (emulsified in CFA) subcutane-
ously (s.c.) and analyzed intracellular CTLA-4 expression in Tfh
and Tfr in the draining lymph node (dLN) 7 days later. We identi-
fied Tfr cells as CD4+CXCR5+ICOS+FoxP3+CD19 cells and Tfh
cells as CD4+CXCR5+ICOS+FoxP3CD19 cells (Figure 1A). Tfr
cells had extremely high expression of CTLA-4, whereas
Tfh cells expressed more modest levels of CTLA-4 (Figure 1B).
About 20% of Tfh and ICOS+ (CD4+ICOS+CXCR5FoxP3) cells
expressed CTLA-4, whereas CD4+ICOSCXCR5 FoxP3 (DN)
cells, a gate comprising mostly naive cells, had virtually no
CTLA-4 expression (Figure 1C). About 80% of Tfr cells ex-
pressed CTLA-4, which was similar to ICOS+CXCR5 Treg cells
(CD4+ICOS+CXCR5FoxP3+).
Because ICOS+CXCR5 Treg cells highly express CTLA-4, we
next determined whether ICOS and CTLA-4 expression were
similarly high on Tfr cells. Costaining of dLN Tfr cells revealed
that high ICOS expression correlated with high CTLA-4 expres-
sion (Figure 1D). Because increased IRF4 expression correlates
with suppressive function in Tfr cells (Sage et al., 2013), we also
costained Tfr cells for CTLA-4 and IRF4. IRF4 expression also
correlated with increased CTLA-4 expression (Figure 1E). We
next asked whether CTLA-4 is a marker for proliferating Tfr cells
by using Ki67 to identify actively cycling cells. There was only a
small increase in CTLA-4 expression on Ki67+ cells compared
to Ki67 Tfr cells (Figure 1F). In addition, we investigatedwhether
high CTLA-4 expression correlated with PD-1 expression.
CTLA-4 expression was only slightly higher on cells highly ex-
pressing PD-1 compared to cells with intermediate levels of
PD-1 (Figure 1G). Together, these data indicate that CTLA-4
expression in Tfr cells correlates with ICOS and IRF4 and to a
lesser extent with Ki67 and PD-1 expression.
We also compared CTLA-4 expression on Tfr cells from
different anatomical locations, because these cells are not only
found in the draining LN and spleen, but also in the circulation,
Peyer’s patches (PP), and skin (Kawamoto et al., 2014; Sage
et al., 2013, 2014; Tsuji et al., 2009). Although not completely un-
derstood, Tfh (and Tfr) cells in the circulation have been postu-
lated to represent distinct subsets and might represent memoryImmcells (Craft, 2012; He et al., 2013; Locci et al., 2013; Sage et al.,
2014; Sage et al., 2013). Most Tfr cells were positive for CTLA-4
regardless of their anatomical location (Figures 1H and 1I). How-
ever, Tfr cells from different anatomical locations had distinct
surface-expression levels of ICOS (Figure 1J). These data indi-
cate that CTLA-4 expression in Tfr cells is universal and expres-
sion correlates with functionally competent Tfr cells.
Inducible Global Deletion of CTLA-4 Results in
Increased Tfr Differentiation and Increased Germinal
Center B Cells
To assess the role of CTLA-4 in regulating B cell responses, we
developed inducible deletion strategies. We crossed Ctla4
floxed mice with UBC-ERT2-Cre (referred to as UBC-iCre) trans-
genic mice so that CTLA-4 could be deleted on all cells after the
administration of tamoxifen (A.M.P. and A.H.S., unpublished
data). We gave tamoxifen to UBC-iCre+Ctla4F/F or UBC-iCre-
Ctla4F/F mice 3 days before immunization with NP-OVA (Fig-
ure 2A) to optimally and specifically delete CTLA-4 at the time
of immunization. CTLA-4 was deleted on most Tfr and Tfh cells
(Figure 2B; see also Figures S1A and S1B available online).
Importantly, unlike germline deletion of CTLA-4, deletion of
CTLA-4 in adult UBC-Cre mice did result in spontaneous inflam-
mation during the immunization timeframe (data not shown).
Thus, this strategy allowed us to delete CTLA-4 at the start of im-
munization, while circumventing potential indirect effects related
to T cell development or autoimmunity.
We assessed how deletion of CTLA-4 affected the differentia-
tion and maintenance of Tfh and Tfr cells. Tfh cells in CTLA-4
deleted mice were increased 2-fold compared to controls at
day 9 after immunization (Figure 2C). ICOS expression was
increased substantially on Tfh cells after CTLA-4 deletion (Fig-
ure 2D). Tfr cells were expanded 5 fold after deletion of
CTLA-4, whether expressed as a percentage of total FoxP3+
cells (i.e., the precursors for Tfr cells) or of total CD4+ T cells
on day 9 postimmunization (Figures 2E and 2F). The total number
of Tfr cells was 5-fold greater when CTLA-4 was deleted (Fig-
ure S1D). This increase in Tfr cells was also apparent when other
gating strategies were used to identify Tfr cells (Figure S1C).
Similar to Tfh cells, ICOS expression was also highly upregulated
on Tfr cells after deletion of CTLA-4 compared to controls
(Figure 2G).
To determine the relative proportion of Tfr cells compared to
Tfh cells, we calculated the percentage of Tfr cells in the total
CXCR5+CD4+ T cell population. The relative abundance of Tfr
cells compared to Tfh cells was much higher after deletion of
CTLA-4 compared to control mice in both the dLN and blood
(Figure 2H). Therefore, deletion of CTLA-4 during the initiation
of B cell responses results in increased Tfh and Tfr cells, with
relatively greater increases in Tfr cells, altering the balance of
T cells in the GC toward suppressive Tfr cells.
We next investigated the effect of this marked increase in
Tfr cells on B cell responses in immunized mice in which
CTLA-4 was deleted. We analyzed CD19+GL7+FAS+ GC B
cells from the dLN of mice after immunization as in Figure 2A
and found increased percentages of GC B cells in the dLN af-
ter CTLA-4 deletion (Figure 2I). CD138+ plasma cells, however,
were not substantially increased (Figure S1E). Downregulation,
or transendocytosis, of B7-1 and B7-2 has been proposed tounity 41, 1026–1039, December 18, 2014 ª2014 Elsevier Inc. 1027
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Figure 1. T Follicular Regulatory Cells Express High Amounts of CTLA-4
(A) Gating strategy to identify CD4+ICOS+CXCR5+FoxP3CD19Tfh and CD4+ICOS+CXCR5+FoxP3+CD19 Tfr cells from dLN of immunized mice.
(B) Histograms demonstrating intracellular CTLA-4 expression in Tfh and Tfr cells gated as in (A). DN represents CD4+ICOSCXCRFoxP3 cells and correspond
to naive CD4+ T cells. Inset numbers indicate mean fluorescence intensity (MFI).
(C) Quantification of intracellular CTLA-4 expression in FoxP3 and FoxP3+ cellular subsets. DN represents CD4+ICOSCXCR5, ICOS+ represents CD4+
ICOS+CXCR5.
(D) CTLA-4 expression correlates with ICOS expression. Staining of ICOS and CTLA-4 in Tfr cells (left). Quantification of CTLA-4 in Tfr cells with intermediate (int)
or high (hi) ICOS expression (right).
(E) CTLA-4 expression correlates with IRF4 expression. Staining of IRF4 and CTLA-4 in Tfr cells (left). Quantification of CTLA-4 in Tfr cells with intermediate (int) or
high (hi) IRF4 expression (right).
(F) CTLA-4 and Ki67 expression. Staining of Ki67 and CTLA-4 in Tfr cells (left). Quantification of CTLA-4 in Tfr cells positive (+) or negative () for Ki67 expression
(right).
(G) CTLA-4 and PD-1 expression. Staining of PD-1 and CTLA-4 in Tfr cells (left). Quantification of CTLA-4 in Tfr cells with intermediate (int) or high (hi) PD-1
expression (right).
(H and I) CTLA-4 expression in Tfr cells from dLN, blood (BL), or PP. DN represents CD4+ICOSCXCR5FoxP3 cells. Quantification is shown (I).
(J) ICOS expression on Tfr cells from dLN, blood, and PP in as in (H).
All error bars contain SE.
Immunity
CTLA-4 on Tfh, Tfr, and Treg cellsbe one mechanism by which CTLA-4 can control immune re-
sponses (Qureshi et al., 2011). We found no substantial
changes in B7-1 or B7-2 expression on GC B cells in immu-
nized CTLA-4-deleted mice compared to controls (Figure 2J).
However, expression of B7-2 (but not B7-1) was significantly
increased on total B cells in CTLA-4-deleted mice compared
to controls.
To determine whether the increase in GC B cells resulted in
increased antibody levels, we measured total immunoglobulin
G1 (IgG1), total IgE, and NP-specific IgG1. Total IgG1 was higher
in CTLA-4-deleted mice at d21. However, surprisingly, we did1028 Immunity 41, 1026–1039, December 18, 2014 ª2014 Elsevier Innot find increases in antigen-specific antibody (Figure 2K). Inter-
estingly, total IgE was much higher at d14 and d21 after immuni-
zation. To determine whether there were any spontaneous
changes in serum Ig levels in unimmunized UBC-iCre+Ctla4F/F
mice at a later time point after deletion, we also assessed serum
antibody levels in unimmunized UBC-iCre+Ctla4F/F mice
240 days after deletion. We found increases in IgG1 and IgE
serum levels in these unimmunized CTLA-4-deleted mice (Fig-
ure 2L). Together, these data indicate that selective deletion of
CTLA-4 at the time of initiation of a humoral immune response re-
sults in increased Tfh cells and an even greater increase in Tfrc.
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Figure 2. Inducible Global Deletion of CTLA-4 Results in Increased Tfr Cell Differentiation and Increased Germinal Center B Cells
(A) Schematic diagram of inducible deletion strategy to study the role of CTLA-4 in regulating B cell responses. UBC-iCreCtla4F/F or UBC-iCre+Ctla4F/F mice
were given tamoxifen daily for 3 days and on the third day, immunized with NP-OVA s.c.; 9 or 21 days later, dLN or blood was harvested for analysis.
(B) Histogram demonstrating deletion of CTLA-4 in Tfh and Tfr cells. Tfh and Tfr cells were gated as in Figure 1A. Inset numbers indicate MFI.
(C) Tfh cell numbers are increased after total deletion of CTLA-4. Representative histograms of Tfh cell gating (left, at d9) and quantification of Tfh cells (right, at d9
and d21).
(D) Increased ICOS expression on Tfh cells after CTLA-4 deletion. ICOS expression on Tfh cells gated as in (C) at d9 postimmunization.
(E) Increased Tfr cell percentages after deletion of CTLA-4. Representative histograms of Tfr cell gating (left, at d9) and quantification of Tfr cells (right, at d9 and
d21 postimmunization). Tfr cell percentages reported as a percentage of all CD4+ T cells.
(F) Tfr cell percentages reported as a percentage of all FoxP3+ T cells 9 days after immunization.
(G) ICOS expression on Tfr cells 9 days after immunization.
(H) Tfr cell percentage of total CD4+CXCR5+ T cells 9 or 21 days after immunization.
(I) Enhanced germinal center B cells after CTLA-4 deletion. Gating of CD19+GL7+FAS+ germinal center (GC) B cells (left, at d9). Quantification of GC B cells
(middle at d9, and right at d21 after immunization).
(J) Quantification of B7-1 and B7-2 on GC and total B cells from (I) 9 days after immunization.
(K) Quantification of serum antibody levels 14 and 21 days after immunization for total IgG1 (left), NP specific IgG1 (middle), or IgE (right).
(L) Quantification of serum antibody levels 240 days after CTLA-4 deletion in unimmunized mice. See also Figure S1.
All error bars contain SE.
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Figure 3. CTLA-4 Inhibits Tfh Stimulation of B Cells
(A) Schematic diagram of experimental approach. 10–20 UBC-iCre or UBC-iCre+ Ctla4F/F Foxp3IRES-GFP mice were immunized with NP-OVA s.c., and 4 days
later tamoxifen was administered i.p.; 3 days later CD4+ICOS+CXCR5+FoxP3CD19 (Tfh) cells were sorted and plated with CD19+ cells (from dLN of immunized
iCre control mice) along with anti-CD3, anti-IgM, and 4OHT for 6 days.
(B) Histogram demonstrating expression of CTLA-4 on Tfh cells in stimulation assay after deletion. Numbers indicate percent positive based on gate.
(C) Enhanced stimulatory capacity of Tfh cells after deletion of CTLA-4. B cells from cocultures as in (A) were stained for GL7 and intracellularly for IgG1 to identify
class-switched B cells. Gating strategy (left) and quantification (right).
(D) Enhanced stimulatory capacity of Tfh cells after deletion of CTLA-4 using NP-OVA. Cocultures were performed as in (A) but NP-OVA was added to wells
instead of anti-CD3/IgM. 6 days later supernatants were analyzed for IgG.
(E) Expression of B7-1 (left) and B7-2 (right) on B cells from stimulation assays as in (A).
(F) Intracellular expression of Ki67 in Tfh cells from stimulation assays as in (A)
(G) CTLA-4 expression in Tfh cells frommice defined in (A) and also with Cre+ mice injected with tamoxifen in vivo but not cultured with 4OHT to achieve the 50%
Tfh deletion of CTLA-4.
(H) CTLA-4 inhibits Tfh stimulatory function in a cell intrinsic manner. Expression of Ki67 in CTLA-4 nonexpressing () or CTLA-4 expressing (+) Tfh cells from
stimulation assays. See also Figure S2.
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body levels.
Deletion of CTLA-4 in Tfh Cells Results in Enhanced
Stimulatory Capacity
Next we assessed whether selective deletion of CTLA-4 on Tfh
cells during the effector phase alters their stimulatory capacity.
To do this, we utilized an in vitro B cell stimulation assay. We
immunized UBC-iCre+Ctla4F/FFoxp3IRES-GFP or UBC-iCre
Ctla4F/FFoxp3IRES-GFP mice and sorted Tfh (CD4+ICOS+CXCR5+
FoxP3CD19) cells from dLNs. The sorted Tfh cells were
cultured with wild-type (WT) B cells (from dLN of NP-OVA immu-
nized mice) in the presence of anti-CD3, anti-IgM, and 4-hy-
droxy-tamoxifen (4OHT) for 6 days (Figure 3A). After culture,
control iCre Tfh cells had substantial CTLA-4 expression, but
use of tamoxifen in vivo combined with culture in 4OHT resulted
in substantial deletion of CTLA-4 in iCre+ Tfh cells (Figure 3B).
To compare the capacity of CTLA-4 deleted and expressing
Tfh cells to stimulate B cell class-switch recombination, we
analyzed B cells from cultures. CTLA-4 deleted Tfh cells stimu-
lated B cells to undergo class-switch recombination to IgG1 to
a greater extent than CTLA-4 expressing (iCre) Tfh cells (Fig-
ure 3C). This increase in class-switch recombination was1030 Immunity 41, 1026–1039, December 18, 2014 ª2014 Elsevier Inaccompanied by increases in IgG in culture supernatant when
NP-OVA was used to stimulate cells (Figure 3D). Despite in-
creases in antibody, there were comparable numbers of Tfh
cells, resulting from slight increases in cell death offsetting
increased proliferation (Figure S2A). B cells were comparable
in number and were phenotypically similar (Figures S2A–S2D).
B cells from anti-CD3 and anti-IgM stimulation assays had
similar upregulation of B7-1 and B7-2 expression after culture
with CTLA-4-expressing or CTLA-4-deleted Tfh cells (Figure 3E).
Because we have found that Ki67 expression in Tfh cells func-
tionally predicts their stimulatory capacity (Sage et al., 2014),
we analyzed Ki67 expression in Tfh cells after coculture with B
cells. Ki67 was increased in CTLA-4 deleted Tfh cells compared
to CTLA-4 expressing controls (Figure 3F).
To determine whether this increase in Ki67 is a cell-intrinsic or
cell-extrinsic effect of CTLA-4 deletion in these stimulation as-
says, we cultured B cells with CTLA-4 control (iCre cultured
with 4OHT), CTLA-4 deleted (iCre+ cultured with 4OHT) or
CTLA-4 50% deleted from Tfh (iCre+ mice injected with tamox-
ifen in vivo but not cultured with 4OHT to achieve the 50%
Tfh deletion of CTLA-4). This strategy enabled us to compare a
range of CTLA-4 deleted Tfh cells (Figure 3G). We compared
Ki67 expression in the CTLA-4 expressing and CTLA-4c.
Immunity
CTLA-4 on Tfh, Tfr, and Treg cellsnonexpressing populations and found that Tfh cells with deleted
CTLA-4 had a higher percentage of Ki67-positive cells
compared to Cre controls, but that CTLA-4 expressing cells
in the same well as CTLA-4 deleted cells did not have an
increased percentage of Ki67-positive cells (Figure 3H). These
experiments show that CTLA-4 has a cell-intrinsic function in
Tfh cells to suppress their stimulatory function.
Inducible Deletion of CTLA-4 in Treg Cells Results
in Increased Tfr Cells and Increased Germinal Center
B Cells In Vivo
We next investigated the role of CTLA-4 on Tfr cells. We bred
Ctla4 floxed mice to Foxp3-ERT2-Cre-GFP knockin (Rubtsov
et al., 2010) (referred to as Foxp3iCre/iCre) mice to generate a
mouse strain that conditionally deletes CTLA-4 only on FoxP3+
Treg cell subsets only after administration of tamoxifen. This
strategy allows for deletion of CTLA-4 on Tfr cells (and other
FoxP3+ Treg subsets) at the time of immunization, circumventing
lethal spontaneous inflammation associated with germline dele-
tion of CTLA-4 on FoxP3+ Treg cells. We gave tamoxifen to
Foxp3iCre/iCreCtla4F/F (referred to as F/F) or Foxp3iCre/iCreCtla4F/+
(referred to as F/+) mice daily for 3 days and immunized with NP-
OVA (Figure 4A). Tamoxifen deleted CTLA-4 in Tfr cells from F/F
mice but not F/+mice (Figures 4B and 4C and Figures S3A–S3C).
Notably, Foxp3
iCre/iCre
mice have attenuated percentages of Tfr
cells expressing CTLA-4 and lower T cell CXCR5 expression
compared to non-Cre expressing mice, a phenomenon that is
due to altered FoxP3 expression related to the Foxp3iCre knockin
allele and not due to CTLA-4 floxed alleles (Figure S3B). We
controlled for this alteration by comparing Foxp3iCre/iCreCtla4F/F
and Foxp3iCre/iCreCtla4F/+ mice. When we analyzed Tfr develop-
ment in these strains, we found substantial increases in Tfr cells
in CTLA-4 Treg-deleted mice compared to controls (Figure 4D
and Figures S3D and S3E). The increase in Tfr cells in CTLA-4
Treg-deleted mice was due, in part, to substantial increases in
total Treg cells (Figure 4E). Additionally, Tfr ICOS expression
was greatly enhanced upon deletion of CTLA-4 (Figure 4F).
The substantial increase in Tfr cells upon deletion of CTLA-4
was also associated with a very modest decrease in cell death
(Figure 4G). Therefore, deletion of CTLA-4 in Treg cells results
in enhanced Tfr differentiation and/or maintenance associated
with increased ICOS expression.
Next we determined whether deletion of CTLA-4 on Treg cells
changed the differentiation and/or phenotype of Tfh cells. We
found significant increases in the percentage of Tfh cells in
immunized mice that had CTLA-4 deleted on Treg cells (Fig-
ure 4H). Unlike total deletion of CTLA-4, however, Tfh cells in
the dLN did not have a significant increase in ICOS expression
as a result of deletion of CTLA-4 on Treg cells (Figure 4I).
When we compared the percentage of Tfr cells in all CXCR5+
CD4+ T cells (and therefore the percentage of Tfr cells of all
CD4 effectors in the GC), we found that Tfr cells comprised a
much higher proportion of the CXCR5+ CD4+ T cell population
in CTLA-4 Treg-deleted mice, compared to control mice
(Figure 4J).
We next investigated GC B cells in the immunized CTLA-4
Treg-deleted mice to determine whether deletion of CTLA-4 on
Treg cell subsets can recapitulate the enhanced GC B cells
observed in mice in which CTLA-4 is inducibly deleted globallyImm(UBC-Cre). We analyzed GL7+FAS+ GC B cells and found that
deletion of CTLA-4 on Tfr and other Treg cell subsets resulted
in increasedGCB cell percentages and total numbers compared
to controls (Figure 5A and Figure S4A). The increased GC B cells
in CTLA-4 Treg-deleted mice had almost identical expression of
B7-1 and B7-2 compared to nondeleted control mice (Figure 5B-
C). However, total B cells had slightly higher expression of B7-2
(but not B7-1) after deletion of CTLA-4 on Treg cells, similar to
global inducible CTLA-4 deletion. Despite increases in GC B
cells, total serum IgG1 was not significantly altered in CTLA-4
deleted mice (Figure 5D). The increase in GC B cells was not
be recapitulated in other Cre strains such as CD19 Cre (which
deletes CTLA-4 on B cells) (Figure S4B). Together, these data
indicate that selective deletion of CTLA-4 on Treg cell subsets
at the beginning of antigen challenge results in increased Tfh
cells and Tfr cells (with a marked increase in Tfr to Tfh ratio)
and increased GC B cells.
Inducible Deletion of CTLA-4 on Tfr Cells after
Differentiation Results in Decreased Suppressive
Function In Vitro and In Vivo
Although GC B cells were increased in both the global and Treg-
specific CTLA-4 deletion models, we did not find significant
changes in antigen-specific antibody responses (although we
didmeasure increases in total IgE and IgG1 after global deletion).
We hypothesized that increases in Tfr cell numbers upon dele-
tion of CTLA-4 might compensate for defective suppressive ca-
pacity of Tfr cells. Therefore, we further examined the role of
CTLA-4 specifically on Tfr cells in regulating Tfr suppressive
function. First, we assessed the effect of CTLA-4 on Tfr cell sup-
pression utilizing in vitro suppression assays. We immunized
UBC-iCre+Ctla4F/FFoxp3IRES-GFP (iCre+) or UBC-iCreCtla4F/F
Foxp3 IRES-GFP (WT) control mice with NP-OVA, gave tamoxifen
on d4 (to start the deletion process so CTLA-4 can be efficiently
deleted at the start of the in vitro assay) and sorted Tfr (sorted as
CD4+ICOS+CXCR5+FoxP3+CD19) cells on d7. The Tfr cells
were cultured with B cells and Tfh cells (both sorted from immu-
nized UBC-iCre Ctla4F/FFoxp3 IRES-GFP WT mice) in the pres-
ence of anti-IgM, anti-CD3, and 4-OHT (Figure 6A-B). Impor-
tantly, precultured cells did not have any change in
differentiation or surface phenotype because CTLA-4 had not
been fully deleted (Figure S5A).
When we analyzed B cells from suppression assays, we found
that WT Tfr cells almost completely suppressed class-switch
recombination to IgG1, whereas iCre+ Tfr cells suppressed
class-switch recombination to IgG1 slightly less well (Figures
6C and 6D). Conventional Treg cells (sorted as CD4+FoxP3+
ICOSCXCR5) were able to attenuate class-switch recombina-
tion, but to a much lesser degree compared to Tfr cells (Fig-
ure 6D). Similar to Tfr cells, suppression by conventional Treg
cells was attenuated with CTLA-4 deletion (Figure 6D). The dif-
ference in B cell responses after CTLA-4 deletion on Tfr cells
was not due to altered Tfr numbers (Figure S5B). We have found
that downregulation of theGC activationmarker GL7 onB cells is
more sensitive than class-switch recombination in determining
Tfr suppressive capacity. The reduced suppressive capacity of
CTLA-4 deleted Tfr cells was also evidenced by the increased
percentage of GL7+ B cells in cultures with CTLA-4 deleted Tfr
cells (Figure 6E). Despite small changes in suppressive function,unity 41, 1026–1039, December 18, 2014 ª2014 Elsevier Inc. 1031
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Figure 4. Inducible Deletion of CTLA-4 in Treg Cells Results in Increased Tfr and Tfh Cells
(A) Schematic diagram of experiment. Foxp3iCre/iCreCtla4F/+ or Foxp3iCre/iCre Ctla4F/F mice were injected with tamoxifen daily for 3 days before immunization with
NP-OVA s.c. 9 or 21 days later dLN and blood were collected for analysis.
(B) Histogram showing deletion of CTLA-4 in Tfr cells. Cre ICOSCXCR5FoxP3 cells (Cre- DN FoxP3) are included as controls. Inset numbers indicate MFI.
(C) Quantification of CTLA-4 staining in Tfr cells.
(D) Increased Tfr cell percentages after Treg cell-specific deletion of CTLA-4. Representative Tfr staining, gated on FoxP3+ cells (left, at d9), and Tfr quantification,
as a percentage of total CD4+ T cells (right, at d9 and d21).
(E) Quantification of FoxP3+ cells after Treg cell-specific CTLA-4 deletion 9 and 21 days after immunization.
(F) Increased ICOS expression on Tfr cells after CTLA-4 deletion. ICOS expression was quantified on Tfr cells 9 and 21 days after immunization.
(G) Cell death of Tfr cells after deletion of CTLA-4 in vivo. Cell death in Tfr cells and total Treg cells was measured by staining with the activated caspase staining
reagent VAD-FMK 9 days after immunization.
(H) Increased Tfh cell percentages after Treg cell-specific CTLA-4 deletion. Representative gating (left, at d9) and quantification (right, at d9 and d21) is shown.
(I) ICOS expression on Tfh cells after Treg-specific CTLA-4 deletion 9 or 21 days after immunization.
(J) Tfr cells are more abundant compared to Tfh cells in the germinal center. Percentage of Tfr cells of all CD4+CXCR5+ cells is shown 9 or 21 days after im-
munization. See also Figure S3.
All error bars contain SE.
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Figure 5. Inducible Deletion of CTLA-4 in
Treg Cells Results in Increased Germinal
Center B Cells In Vivo
(A) Enhanced GC B cell responses after Treg cell-
specific deletion of CTLA-4. Foxp3iCre/iCre Ctla4F/+
or Foxp3iCre/iCre Ctla4F/F mice were injected with
tamoxifen daily for 3 days before immunization
with NP-OVA s.c. 9 or 21 days later, dLN was
collected for analysis.
(B and C) Expression of B7-1 and B7-2 on total
CD19+ B cells or on CD19+GL7+FAS+ GC B cells
9 days after immunization. Representative histo-
grams (B) and quantification (C) are shown.
(D) Serum IgG1 levels. Serum IgG1 was analyzed
in mice 14 or 21 days after immunization as in (A).
See also Figure S4.
All error bars contain SE.
Immunity
CTLA-4 on Tfh, Tfr, and Treg cellsthe CTLA-4 deleted Tfr cells were able to suppress B7-1 expres-
sion levels on the surface of B cells similarly to WT Tfr cells
(Figure 6F).
Activated Tfh cells cultured with B cells upregulate Ki67 and
maintain levels of the transcription factor Bcl6 (Sage et al.,
2014). When we assessed Bcl6 and Ki67 levels in Tfh cells in
these suppression assays, we found that WT Tfr cells attenuated
Tfh Bcl6+Ki67+ levels by 70 percent, in marked contrast to
CTLA-4 deleted Tfr cells, which were only able to attenuate Tfh
Bcl6+Ki67+ levels by 30 percent (Figure 6G). The difference in
suppression was not due to altered B cell IDO, Tfr GITR, or Tfr
IL-10 production (Figures S5C–S5E). Together, these data indi-
cate that deletion of CTLA-4 during the effector phase dimin-
ishes Tfr suppressive capacity.
To determine whether deletion of CTLA-4 results in cell-
intrinsic differences in the activation state of the Tfr cell, we
developed a plate-bound assay to signal through CD28 and
CTLA-4 in Tfr cells in the absence of other cell types. In this
assay, we cultured sorted WT or iCre+ Tfr cells on anti-CD3
and rB7-2-Fc coated plates. B7-2 was used, and not B7-1, to
eliminate the possibility of B7-1 signaling into the Tfr cell through
a B7-1:PD-L1 interaction (Butte et al., 2007). During culture, we
eliminated CTLA-4 on Tfr cells with 4OHT and analyzed cultures
4 days later. We found that deletion of CTLA-4 on Tfr cells did not
result in loss of FoxP3 expression but resulted in higher ICOS
expression (Figures S5F and S5G).
Next we determined whether deletion of CTLA-4 only on Tfr
cells andonly during suppression alteredBcell responses in vivo.
To do this, we immunized Foxp3iCre/iCreCtla4F/+ or Foxp3iCre/iCre
Ctla4F/F mice with NP-OVA s.c. and 6 days later gave tamoxifen
to start deletion. Twenty-four hr later, we sorted total CD4+
CXCR5+ICOS+CD19 cells (which contain Tfh and Tfr cells, but
not other cellular subsets) and adoptively transferred these cells
to Cd28/ mice (which cannot generate Tfh and Tfr cells) that
were then immunized with NP-OVA and given tamoxifen (Fig-
ure 6H). Because the transferred cells have an inducible Cre un-
der the FoxP3 promoter, and only Tfh and Tfr cells were trans-Immunity 41, 1026–1039, Deferred, administration of tamoxifen to
the recipients deletes CTLA-4 only on
Tfr cells. When we analyzed recipients af-
ter adoptive transfer and deletion, wefound that deletion of CTLA-4 on Tfr cells led to an overall in-
crease in Tfh cells in recipients (Figure 6I), and this increase
was not due to Tfr cell conversion into Tfh cells (Figure S5I).
These results show that CTLA-4 deleted Tfr cells have reduced
ability to suppress Tfh cells compared to control Tfr cells. Impor-
tantly, deletion of CTLA-4 on Tfr cells led to a substantial in-
crease in NP-specific IgG, demonstrating diminished suppres-
sive capacity of downstream B cell responses by Tfr cells after
CTLA-4 deletion (Figure 6J). Although it is likely that this antibody
originates from the GC responses, extrafollicular pathways
might also contribute. The increased antibody produced in Tfr
CTLA-4-deleted mice had a lower NP2/NP16 ratio, suggesting
that the increased antibody might be of lower affinity (Fig-
ure S5H). Additionally, GC B cell numbers and plasma cell per-
centages were increased, although this did not reach statistical
significance (Figure S5H). Unlike Tfr cells, conventional Treg
cells were not able to suppress Tfh-mediated antigen-specific
antibody production inCd28/ recipients (Figure S5J). Although
we found substantial increases in antigen-specific antibody re-
sponses upon deletion of CTLA-4 in Tfr cells, B7-1 and B7-2
expression on GC and total B cells were not altered (Figures 6K
and 6L). Together, these data indicate that CTLA-4-deleted Tfr
cells exhibit defective B cell suppression using in vitro and in vivo
assays of Tfr cell function.
Deletion of CTLA-4 in Tfr Cells Results in Enhanced B
Cell Responses in Peyer’s Patches
Because Tfr cells and Tfh cells are present in the germinal cen-
ters of PP (Kawamoto et al., 2014), we also investigated whether
deletion of CTLA-4 in Tfr cells affects B cell responses in PP of
the gut using both the UBC-iCre+ CTLA-4F/F and Foxp3iCre/iCre
CTLA-4F/F strains. We gave mice from each strain tamoxifen
on 3 consecutive days, and analyzed PP for Tfh, Tfr, and B cell
responses at several time points after tamoxifen administration.
Global inducible deletion of CTLA-4 resulted in substantial dele-
tion of CTLA-4 in both Tfh and Tfr cells of PP, similar to LN drain-
ing sites of immunization (Figures S6A and S6B). Total, but notcember 18, 2014 ª2014 Elsevier Inc. 1033
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Figure 6. Inducible Deletion of CTLA-4 on Tfr Cells during Suppression Results in Decreased Suppressive Function In Vitro and In Vivo
(A) Schematic representation of experiment. Twenty UBC-iCreCtla4F/FFoxp3IRES-GFP (WT) or UBC-iCre+Ctla4F/FFoxp3IRES-GFP (iCre) mice were immunized
with NP-OVA s.c. and 4 days later mice were given tamoxifen i.p.; 3 days later CD4+ICOS+CXCR5+FoxP3CD19 (Tfh) and CD19+ B cells from iCre- WT mice
were cultured with anti-CD3, anti-IgM, and 4OHT. CD4+ICOS+CXCR5+FoxP3+CD19 Tfr cells from WT or iCre+ mice were added. Cells were analyzed 6 days
later.
(B) Deletion of CTLA-4 in Tfr cells after suppression assay as in (A). Tfr cells from cultures were identified as CD4+FoxP3+CD19 cells.
(C) Deletion of CTLA-4 in Tfr cells results in decreased suppression of class-switch recombination. Representative plots of B cells showing GL7+IgG1+ class-
switched B cells from suppression assays detailed in (A; left). Quantification of class-switched B cells (right).
(D) Effect of deletion of CTLA-4 in conventional Treg cells in suppression assays. Experiments were performed as in (A) except CD4+ICOSCXCR5FoxP3+
conventional Treg cells, or Tfr cells, were cultured with B cells. ‘‘Control’’ indicates B cells alone.
(E) GL7 expression on B cells from suppression assays as in (A).
(F) B7-1 expression on B cells from suppression assays as in (A).
(G) Deletion of CTLA-4 in Tfr cells results in decreased suppression of Tfh cells. Tfh cells from suppression assays in (A) were intracellularly stained for Ki67 and
Bcl6. Tfh cells were identified as CD4+FoxP3CD19 cells from cultures. Representative plots are shown.
(H) Deletion of CTLA-4 in Tfr cells after differentiation results in diminished suppressive capacity in vivo. Schematic representation of assay. Foxp3iCre/iCreCtla4F/F
or Foxp3iCre/iCreCtla4F/+ mice were immunized and tamoxifen was administered 1 day before sorting total CD4+ICOS+CXCR5+CD19 (Tfh and Tfr) cells on day 6.
Sorted cells were adoptively transferred toCd28/mice that were immunizedwith NP-OVA and tamoxifen was administered on days 0 and 1 after immunization.
Organs were harvested 9 days later for analysis.
(I) Quantification of Tfh cells in recipient mice from transfers in (H).
(J) NP-specific IgG serum levels from recipient mice in transfers as in (H).
(K) B7-1 and (L) B7-2 expression on total CD19+ (B) or CD19+GL7+FAS+ (GC B) B cells from transfers in (H). See also Figure S5.
All error bars contain SE.
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Immunity
CTLA-4 on Tfh, Tfr, and Treg cellsTreg cell-specific, deletion of CTLA-4 resulted in slight in-
creases in PP Tfh cell percentages (Figure 7A-B). In contrast,
Tfr cells were enhanced as a percentage of CD4+ (or of
FoxP3+) cells when CTLA-4 was deleted global or selectively in
Treg cells (Figure 7C and Figure S6C), and proportions of Tfr cells
were increased compared to Tfh cells using both approaches
(Figure 7D). Therefore, in the absence of CTLA-4 on Treg cells,
there are increased Tfr percentages in PP, similar to skin dLNs.
Next we investigated B cell responses in the PP frommicewith
global and Treg cell-specific deletion of CTLA-4. CTLA-4 dele-
tion resulted in an increase in GC B cells, but not plasma cells,
in PP (Figure 7E and Figure S6D). Deletion of CTLA-4 on all cells
or Treg cells did not alter B7-1 or B7-2 expression on GC B cells
(Figures 7F and 7G). However, as in skin dLNs, we did detect
small but significant increases in expression levels of B7-2, but
not B7-1, on total B cells after CTLA-4 deletion compared to non-
deleted controls. Importantly, serum IgA levels were increased in
mice after CTLA-4 deletion compared to nondeleted controls
(Figure 7H). Together, these data indicate that deletion of
CTLA-4 in Treg cells results in defective suppression, manifest
as enhanced B cell responses in the PP. This phenotype mirrors
the phenotype of skin dLN, suggesting that altered function of
B cell responses in the PP in CTLA-4-deleted mice might be
due to defective Tfr function.
DISCUSSION
Although CTLA-4 has been implicated in modulating B cell re-
sponses, the inability to selectively delete or inhibit CTLA-4 on
defined cell types has led to confusion about the precise role(s)
of CTLA-4 in controlling humoral immunity (Walker and Sansom,
2011). Here we utilize inducible CTLA-4 gene deleted mice to
assess the role of CTLA-4 in B cell responses and identify func-
tions for CTLA-4 on multiple T cell subsets in regulating humoral
immunity. We find that CTLA-4 inhibited Tfh cell differentiation
and/or maintenance and effector function. In addition, CTLA-4
potently inhibited Tfr cell differentiation and/or maintenance
but was required in vivo for Tfr cells to fully suppress antigen-
specific B cell responses in germinal centers. We also find evi-
dence that non-Tfr Treg cells and/or Tfr cells might suppress B
cell responses by CTLA-4-mediated downregulation of B7-2
presumably outside the germinal center. Therefore our work un-
covers multiple roles for CTLA-4 on Tfh, Tfr, and Treg cells in
regulating humoral immunity.
Global deletion of CTLA-4 at the time of immunization resulted
in increased Tfh cells. Treg-specific deletion of CTLA-4 also re-
sulted in increased Tfh cell differentiation but was not as
substantial as global CTLA-4 deletion. Therefore, Tfh cells are
regulated by Tfh-expressed CTLA-4, as well as Tfr-expressed
CTLA-4.However, it is important to note that theremight bediffer-
ences in the deletion models, which alter Tfh percentages. For
instance, in the Treg cell-specific CTLA-4 deletion model, control
mice have only one functional allele of CTLA-4. Beyond differen-
tiation, CTLA-4 also inhibits the B cell stimulatory function of Tfh
cells, consistentwithprevious studies that demonstrate a specific
role for CTLA-4 on T conventional cells, presumably separately
from Treg cells (Greenwald et al., 2001; Ise et al., 2010; Walker,
2013; Walker et al., 2002). We did not detect any substantial
changes in B7-1 or B7-2 levels on B cells from Tfh and B cell co-Immcultures. Furthermore, cultures of B cells with CTLA-4 expressing
plus CTLA-4 nonexpressing Tfh cells revealed cell intrinsic func-
tional differences between these Tfh cell populations. Therefore,
CTLA-4 likely functionally impedes Tfh cell differentiation and
B cell stimulation by altering signaling into Tfh cells.
The machinery responsible for limiting Tfr cell differentiation
and function are still relatively unknown. Previous studies have
demonstrated roles for PD-1, Blimp-1, and Id2/Id3 in inhibiting
Tfr differentiation (Linterman et al., 2011; Miyazaki et al., 2014;
Sage et al., 2013). Here we show that CTLA-4 inhibits Tfr cell dif-
ferentiation and/or maintenance. Deletion of CTLA-4 resulted in
enhanced Tfr cell differentiation that was accompanied by sub-
stantially increased ICOS expression. Anti-CTLA-4 therapy simi-
larly increases the frequency of ICOS+ T cells in mouse models
and human patients (Ng Tang et al., 2013).
In marked contrast to PD-1, CTLA-4 does not inhibit but pro-
motes the suppressive capacity of Tfr cells. To assess the role
of CTLA-4 on Tfr cells during suppression, we performed transfer
and deletion studies to circumvent the effects of CTLA-4 on Tfr
cell expansion and/or indirect effects from CTLA-4 on other
cell types. In these experiments, we found clear enhancement
of antigen-specific antibody responses when Tfr cells lacked
CTLA-4. These findings contrast with global or Treg cell-specific
deletion assays of CTLA-4 in which we did not measure
increased antigen-specific antibody production but instead
found increases in total IgG1 and IgE. We hypothesize that the
increase in IgE and total IgG1 during global or Treg cell-specific
CTLA-4 deletion might be due to defective Treg cell and/or Tfr
suppression of B cells outside the germinal center (possibly via
the extra follicular pathway of B cell activation near the T-B
border). This suppression might be at least partially due to
B7-2 downregulation or transcytosis, because we found that
B7-2 expression was lower on total (but not GC) B cells upon
CTLA-4 deletion in both global and Treg cell-specific CTLA-4
deletion models in both the dLN and PP. Although downregula-
tion of B7-2 on total B cells was not observed in Tfr transfer and
CTLA-4 deletion models, these transfer models of fully differen-
tiated Tfr cells might limit the duration of Tfr cells outside the
germinal center due to high CXCR5 expression associated
with full differentiation at the time of transfer.
Although increased total IgG1 and IgE can be explained by
lack of Treg cell (and/or Tfr) suppression through downregulation
of B7-2, enhanced antigen-specific antibody would be expected
in global or Treg cell-specific deletion models if CTLA-4 deleted
Tfr cells were defective in their capacity to suppress GC B cells.
However, we did not observe increased antigen-specific anti-
body responses in global or Treg cell-specific CTLA-4 deleted
mice. We hypothesize that Tfr cells in global or Treg cell-specific
CTLA-4 deleted mice are indeed defective in suppression but
that the substantial increases in Tfr cell numbers during differen-
tiation, combined with suppression mechanisms that are inde-
pendent of CTLA-4, override these defects. We hypothesize
that there might be multiple suppression mechanisms built into
the Tfr program as a means to prevent autoimmunity by allowing
some level of suppression when a single mechanism is faulty.
Additionally, it appears that CTLA-4 deficiency has its own
internal safety measure, in that defective suppression due to
CTLA-4 deletion can be partially overcome by increased expan-
sion of Tfr cells.unity 41, 1026–1039, December 18, 2014 ª2014 Elsevier Inc. 1035
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Figure 7. Deletion of CTLA-4 in Tfr Cells Results in Enhanced B Cell Responses in Peyer’s Patches
(A) Representative gating of Tfh and Tfr cells from PP from UBC-iCre+ Ctla4F/F or UBC-iCre Ctla4F/F mice 9 days after the last dose of tamoxifen administration;
tamoxifen was administered on days 2, 1, and 0.
(B) Quantification of Tfh cells (gated as in A) from UBC-iCre+Ctla4F/F and UBC-iCre-Ctla4F/F mice (left 3 panels) or Foxp3iCre/iCreCtla4F/F and Foxp3iCre/iCreCtla4F/+
mice (far right panel) 9, 21 or 240 days after final tamoxifen treatment.
(C) Quantification of Tfr cells (gated as in A) from UBC-iCre+Ctla4F/F and UBC-iCre-Ctla4F/F mice (left three panels) or Foxp3iCre/iCreCtla4F/F and Foxp3iCre/iCre
Ctla4F/+ mice (far right panel) reported as a percentage of CD4+ cells 9, 21, or 240 days after final tamoxifen treatment.
(D) Quantification of Tfr cells (gated as in A) from UBC-iCre+Ctla4F/F and UBC-iCre-Ctla4F/F mice (left) or Foxp3iCre/iCreCtla4F/F and Foxp3iCre/iCreCtla4F/+ mice
(right) reported as a percentage of total CD4+CXCR5+ cells 9 days after final tamoxifen treatment.
(legend continued on next page)
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CTLA-4 on Tfh, Tfr, and Treg cellsWe did not observe altered B7-1 or B7-2 expression on GC B
cells with CTLA-4-deleted Tfr cells in either our in vitro and in vivo
suppression assays. We propose that Tfr cells in the GC sup-
press B cell responses through CTLA-4 using a mechanism
that does not depend on B7-1 or B7-2 downregulation or trans-
cytosis. It is likely that cell intrinsic signaling is responsible
because we found changes in CTLA-4 deleted Tfr cells in vitro
(such as increased ICOS expression). However, other mecha-
nisms are also possible.
Deletion of CTLA-4 on Tfr cells enhanced Tfh and B cell re-
sponses in PP in addition to skin dLNs. Therefore, our data sug-
gest that CTLA-4 modulation of Tfr and/or Treg cell suppressive
function is not unique to skin dLNs, but instead is a general
mechanism of suppression of B cell responses. Tfr suppression
of IgA has been demonstrated in the gut; however, differences in
IgA and GC B cells were found in the small intestine lamina prop-
ria, but not substantially in the PP (Kawamoto et al., 2014). We
find that the deletion of CTLA-4 on Tfr and Treg cells in PP results
in defective suppression, leading to heightened GC B responses
and serum IgA levels. We hypothesize that this influences the gut
microbiota similar to previous studies demonstrating altered IgA
(Kawamoto et al., 2014; Kawamoto et al., 2012). Further experi-
ments are necessary to investigate these possibilities.
Our work demonstrates that CTLA-4 controls B cell responses
by regulating Tfh, Tfr, and Treg cells. Further work is needed to
determine how modulating CTLA-4 in Tfh, Tfr, and/or Treg cells
could be used to enhance vaccination responses and pathogen
clearance.
EXPERIMENTAL PROCEDURES
Mice
For global inducible deletion of CTLA-4, UBC-ERT2-Cre (Jackson Labora-
tories) mice were crossed to Ctla4 floxed mice to generate UBC-iCre Ctla4F/F
mice (A.M.P. and A.H.S., unpublished data). These mice were also crossed to
Foxp3IRES-GFP reporter mice to visualize FoxP3-expressing cells. UBC-iCre
Ctla4F/F Foxp3GFP/GFP mice were used as controls for UBC-Cre+ Ctla4F/F
Foxp3GFP/GFP experimental mice. For Treg cell-specific deletion of CTLA-4,
Foxp3ERT2-Cre-GFP mice (Jackson Laboratories) were crossed to CTLA-4 floxed
mice to generate Foxp3iCre/iCre Ctla4F/F mice. Foxp3iCre/iCre Ctla4F/+ mice were
used as controls forFoxp3iCre/iCreCtla4F/F experimentalmice to control for small
alterations in Treg cell function due to the Foxp3iCre allele. Cd28/ and CD19-
Cre mice were purchased from Jackson Laboratories. All mice were used ac-
cording to the Harvard Medical School Standing Committee on Animals and
National Institutes of Health Guidelines.
Immunizations
Control and experimental mice were injected with 1 mg tamoxifen (Sigma) in
sunflower oil intraperitoneally (i.p.) daily for 3 days. On the last day, mice
were immunized subcutaneously (s.c.) on the flanks with 100 mg NP-OVA in a
1:1 emulsion in H37RA CFA. Mice were sacrificed and draining inguinal LNs
were harvested. For unimmunized experiments, mice received five injections
of tamoxifen daily and monitored for up to 240 days later. For in vitro assays
of CTLA-4 effector function, UBC-Cre mice were immunized with NP-OVA(E) Increased germinal center B cells after Tfr deletion of CTLA-4 in PP. Identific
mice (representative gating, far left and quantification middle three panels) 9, 21
panel) 9 days after final tamoxifen treatment.
(F and G) B7-1 and B7-2 expression on CD19+ (Total B) or CD19+GL7+FAS+ (GCB
or Foxp3iCre/iCreCtla4F/F and Foxp3iCre/iCreCtla4F/+ mice (G) 9 days after final tamo
(H) Serum IgA levels in UBC-iCre+Ctla4F/F and UBC-iCreCtla4F/F mice 21 or 24
All error bars contain SE.
Imms.c., 5 days later mice received one injection of tamoxifen i.p., and 3 days later
organs were harvested for cell sorting. This strategy was used to maximize
deletion of CTLA-4 at the start of in vitro assays, while simultaneously mini-
mizing effects on differentiation, and was validated by comparing phenotypes
of cells during sorting and by intracellular cytokine staining for CTLA-4.
Flow Cytometry
Cell suspensions were diluted in PBS with 1% FBS with 1 mM EDTA. Samples
were preincubated with Fc block (BioLegend) and stained with the following
directly labeled antibodies: CD4, CD19, ICOS, GL7, B7-1, B7-2, CD138, FAS,
and PD-1. For CXCR5 staining, biotinylated CXCR5 (clone 2G8) was included
in primary surface staining followed by streptavidin-conjugated Brilliant Violet
421 (BioLegend). For intracellular staining, the eBioscience FoxP3 intracellular
staining kit was used. Samples were then incubated with anti-FoxP3, Ki67,
Bcl6, CTLA-4, IRF4, IgG1, IL-17A, IFN-g, IL-21, or IL-4. For cytokine analyses,
samples were preincubated with 500 ng/ml Ionomycin and 250 ng/ml PMA in
the presence of GolgiStop for 4 hr. All samples were analyzed on an LSRII or
sorted on an Aria II with standard laser configurations.
In Vitro Stimulation Assays
For in vitro B cell stimulation assays with Tfh cells, 10–20 UBC-iCre or UBC-
iCre+ mice were immunized with NP-OVA and 5 days later mice received one
injection of tamoxifen. Three days later, the dLNs were harvested and CD4+
ICOS+CXCR5+FoxP3CD19 Tfh cells were sorted. Tfh cells (3 3 104) were
plated with 5 3 104 B cells (sorted as CD19+ cells from lymph nodes of NP-
OVA immunized UBC-iCre mice) along with 2 mg/ml anti-CD3 (BioExcel),
5 mg/ml anti-IgM (Jackson Immunoresearch), and 0.25 nM 4-hydroxy-tamox-
ifen (4OHT; Sigma). Six days later, samples were analyzed.
In Vitro Suppression Assays
For in vitro B cell suppression assays with Tfr cells, UBC-iCre or UBC-iCre+
mice were immunized with NP-OVA and 5 days later mice received one injec-
tion of tamoxifen. Three days later, organs were harvested and 3 3 104 CD4+
ICOS+CXCR5+FoxP3CD19 Tfh cells from iCremice, 53 104 CD19+ B cells
from iCremice, and 1.5 3 104 CD4+ICOS+CXCR5+FoxP3+CD19 Tfr cells
from iCre or iCre+ mice were cultured in the presence of anti-CD3, anti-
IgM, and 0.25 mM 4-hydroxy-tamoxifen (4OHT). Samples were analyzed
6 days later.
Adoptive Transfer Assays
For adoptive transfer studies of Tfr cells in which CTLA-4 was deleted, 20
FoxP3iCre/iCre CTLA-4F/+ or FoxP3iCre/iCre CTLA-4F/F mice were immunized
with NP-OVA s.c. Seven days later, mice received one injection of tamox-
ifen i.p., and 1 day later dLNs were harvested and 8 3 104 CD4+ICOS+
CXCR5+CD19 (Tfh and Tfr cells) were adoptively transferred to CD28/
mice, which were immunized the same day with NP-OVA and given tamox-
ifen i.p. Mice received an additional injection of tamoxifen 1 day later. Mice
were sacrificed 9 days after NP-OVA immunization, and serum and dLNs
were collected.
ELISA
ELISA assays to measure antibody and NP-specific IgG were performed as
previously described (Sage et al., 2013).
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures and can be found with this
article online at http://dx.doi.org/10.1016/j.immuni.2014.12.005.ation of CD19+FAS+GL7+ B cells in UBC-iCre+Ctla4F/F and UBC-iCreCtla4F/F
, or 240 days or Foxp3iCre/iCreCtla4F/F and Foxp3iCre/iCreCtla4F/+ mice (far right
) cells from PP as in (E) fromUBC-iCre+Ctla4F/F and UBC-iCreCtla4F/F mice (F)
xifen treatment.
0 days after last tamoxifen treatment. See also Figure S6.
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